VATS is associated with a lesser postoperative decrease in the numbers of circulating CD3+, CD4+, and CD8+ T cells, which lowers the risk of imbalanced immunoregulation and preserves immunosurveillance, decreasing the risk of tumor growth and recurrence (24, 25). Here, CD8A is linked to neoplasm.